Interviews
Viridis to produce NIMBUS Gauze Dressings
28 Sep '10
2 min read
Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced that its proprietary NIMBUS antimicrobial technology has been approved for manufacture, marketing and sale in India. Viridis BioPharma, an India-based manufacturer and marketer of medical devices, received approval by the Food and Drug Administration (FDA) of India to manufacture and market gauze wound dressings that incorporate NIMBUS antimicrobial technology.
"The approval of our proprietary NIMBUS antimicrobial wound care technology by the India FDA marks an important milestone for both Quick-Med and Viridis," said J. Ladd Greeno, Quick-Med's CEO. "India's large wound care market represents a significant opportunity for Viridis to drive sales with our unique, value-added NIMBUS antimicrobial feature."
Dr. Dilip Mehta, CEO of Viridis BioPharma, commented, "We see this approval to manufacture and market NIMBUS technology based antimicrobial gauze dressings as a paradigm shift in the burn and wound care management. There will be an unparalleled protection afforded against infections to a major percentage of the affected population."
Viridis BioPharma plans to have its first NIMBUS products on the market in the second quarter of 2011.
Quick-Med expects NIMBUS to become an important technology in the $14 billion global wound care market, as wound care companies and health care professionals look for more effective and efficient ways to prevent infections and avoid cross-contamination. By incorporating a non-leaching antimicrobial, bandages with NIMBUS technology can diminish the opportunities for infection and cross-contamination.
Quick-Med's patented technology, NIMBUS is a antimicrobial technology that has been custom designed for wound care and other medical applications. NIMBUS received de Novo FDA clearance in the United States in 2009 and has been commercialized in traditional wound care applications. It is the only non-leaching antimicrobial dressing which, by design, poses no risk of bacteria developing resistance. NIMBUS technology is protected by ten U.S. patents and patents pending and 24 foreign counterparts. Additional applications under development include advanced wound dressings, medical adhesives, and catheters.
"The approval of our proprietary NIMBUS antimicrobial wound care technology by the India FDA marks an important milestone for both Quick-Med and Viridis," said J. Ladd Greeno, Quick-Med's CEO. "India's large wound care market represents a significant opportunity for Viridis to drive sales with our unique, value-added NIMBUS antimicrobial feature."
Dr. Dilip Mehta, CEO of Viridis BioPharma, commented, "We see this approval to manufacture and market NIMBUS technology based antimicrobial gauze dressings as a paradigm shift in the burn and wound care management. There will be an unparalleled protection afforded against infections to a major percentage of the affected population."
Viridis BioPharma plans to have its first NIMBUS products on the market in the second quarter of 2011.
Quick-Med expects NIMBUS to become an important technology in the $14 billion global wound care market, as wound care companies and health care professionals look for more effective and efficient ways to prevent infections and avoid cross-contamination. By incorporating a non-leaching antimicrobial, bandages with NIMBUS technology can diminish the opportunities for infection and cross-contamination.
Quick-Med's patented technology, NIMBUS is a antimicrobial technology that has been custom designed for wound care and other medical applications. NIMBUS received de Novo FDA clearance in the United States in 2009 and has been commercialized in traditional wound care applications. It is the only non-leaching antimicrobial dressing which, by design, poses no risk of bacteria developing resistance. NIMBUS technology is protected by ten U.S. patents and patents pending and 24 foreign counterparts. Additional applications under development include advanced wound dressings, medical adhesives, and catheters.
Quick-Med Technologies Inc
Popular News
Leave your Comments
Esteemed Clients
-Ltd..jpg?tr=w-120,h-60,c-at_max,cm-pad_resize,bg-ffffff "Thermore (Far East) Ltd.")
.jpg?tr=w-120,h-60,c-at_max,cm-pad_resize,bg-ffffff "Telangana State Industrial Infrastructure Corporation Limited (TSllC Ltd)")
.jpg?tr=w-120,h-60,c-at_max,cm-pad_resize,bg-ffffff "Taiwan Textile Federation (TTF)")
